<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01181492</url>
  </required_header>
  <id_info>
    <org_study_id>HuazhongU</org_study_id>
    <nct_id>NCT01181492</nct_id>
  </id_info>
  <brief_title>Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery</brief_title>
  <official_title>Impact of CYP3A4*1G Polymorphism on Metabolism of Fentanyl in Chinese Patients Undergoing Lower Abdominal Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huazhong University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huazhong University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: This study aimed to investigate the impact of CYP3A4*1G genetic polymorphism on
      metabolism of fentanyl in Chinese patients undergoing lower abdominal surgery. Methods: 176
      patients receiving elective lower abdominal surgery under general anesthesia were recruited
      into this study. Genotyping of CYP3A4*1G was carried out by direct sequencing. The plasma
      fentanyl concentration was detected 30 min after anesthesia induction by high performance
      liquid chromatography-ultraviolet ray (HPLC-UV). The visual analog scale (VAS) was used for
      pain evaluation at rest during patient-controlled analgesia (PCA) treatment 0 h, 12 h and 24
      h after operation. PCA fentanyl consumption and adverse effects were recorded during the
      first 24 h after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>CYP3A4*1G Polymorphism</measure>
    <time_frame>48 hours after operation</time_frame>
    <description>According to CYP3A4*1G polymorphism,patients are devided into three groups: *1/*1,*1/*1G,*1G/*1G</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Visual Analog Scale 24 Hours Postoperative</measure>
    <time_frame>24 hours after operation</time_frame>
    <description>The visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCA Fentanyl Consumption</measure>
    <time_frame>24 h after surgery</time_frame>
    <description>PCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">176</enrollment>
  <condition>Pain</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>*1/*1</arm_group_label>
    <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
  </arm_group>
  <arm_group>
    <arm_group_label>*1/*1G</arm_group_label>
    <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
  </arm_group>
  <arm_group>
    <arm_group_label>*1G/*1G</arm_group_label>
    <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      176 blood samples were extracted
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        176 Chinese patients receiving elective lower abdominal surgery under general anesthesia
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 20-65 years

          -  Anesthesiologists (ASA) physical status I or II;

          -  With ±20% of ideal body weight;

          -  Received PCA administration;

          -  Agreed to participate the research

        Exclusion Criteria:

          -  History of chronic pain;

          -  Psychiatric diseases;

          -  Diabetes mellitus;

          -  Severe cardiovascular diseases;

          -  Kidney or liver diseases;

          -  Alcohol or drug abuse (according to the criteria of DSM-IV);

          -  Pregnancy or at lactation period;

          -  Consumed drugs (1week) or foods (3 days) known to inhibit or induce the expression of
             CYP3A4 enzymes prior to surgery;

          -  Refused PCA administration;

          -  Disagree to participate to the research
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhang Xianwei, MD</last_name>
    <role>Study Director</role>
    <affiliation>Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1. Department of Anesthesiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan,</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2010</study_first_submitted>
  <study_first_submitted_qc>August 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2010</study_first_posted>
  <results_first_submitted>December 4, 2012</results_first_submitted>
  <results_first_submitted_qc>August 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 1, 2013</results_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huazhong University of Science and Technology</investigator_affiliation>
    <investigator_full_name>Xianwei Zhang</investigator_full_name>
    <investigator_title>Tongji Hospital, Tongji Medical College</investigator_title>
  </responsible_party>
  <keyword>gene polymorphism</keyword>
  <keyword>CYP3A4</keyword>
  <keyword>fentanyl</keyword>
  <keyword>HPLC</keyword>
  <keyword>Analgesics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, from November 2008 to April 2010 a total of 176 patients were recruited in this study precedure.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>*1/*1</title>
          <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
        </group>
        <group group_id="P2">
          <title>*1/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
        </group>
        <group group_id="P3">
          <title>*1G/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>*1/*1</title>
          <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
        </group>
        <group group_id="B2">
          <title>*1/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
        </group>
        <group group_id="B3">
          <title>*1G/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="103"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="176"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="11.7"/>
                    <measurement group_id="B2" value="47.1" spread="10.1"/>
                    <measurement group_id="B3" value="42.3" spread="7.8"/>
                    <measurement group_id="B4" value="45.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="103"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CYP3A4*1G Polymorphism</title>
        <description>According to CYP3A4*1G polymorphism,patients are devided into three groups: *1/*1,*1/*1G,*1G/*1G</description>
        <time_frame>48 hours after operation</time_frame>
        <population>the number of participants for analysis was determined according to gene type of CYP3A4*1G polymorphism which was carried by participant.</population>
        <group_list>
          <group group_id="O1">
            <title>*1/*1</title>
            <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
          </group>
          <group group_id="O2">
            <title>*1/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
          </group>
          <group group_id="O3">
            <title>*1G/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
          </group>
        </group_list>
        <measure>
          <title>CYP3A4*1G Polymorphism</title>
          <description>According to CYP3A4*1G polymorphism,patients are devided into three groups: *1/*1,*1/*1G,*1G/*1G</description>
          <population>the number of participants for analysis was determined according to gene type of CYP3A4*1G polymorphism which was carried by participant.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="66"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Visual Analog Scale 24 Hours Postoperative</title>
        <description>The visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation</description>
        <time_frame>24 hours after operation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>*1/*1</title>
            <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
          </group>
          <group group_id="O2">
            <title>*1/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
          </group>
          <group group_id="O3">
            <title>*1G/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
          </group>
        </group_list>
        <measure>
          <title>The Visual Analog Scale 24 Hours Postoperative</title>
          <description>The visual analog scale (VAS) is used for pain evaluation at rest which from 0 to 10 (higher values represent morepain) during patient-controlled analgesia (PCA) treatment 24 h after operation</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="1.3"/>
                    <measurement group_id="O2" value="3.7" spread="1.1"/>
                    <measurement group_id="O3" value="3.4" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PCA Fentanyl Consumption</title>
        <description>PCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.</description>
        <time_frame>24 h after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>*1/*1</title>
            <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
          </group>
          <group group_id="O2">
            <title>*1/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
          </group>
          <group group_id="O3">
            <title>*1G/*1G</title>
            <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
          </group>
        </group_list>
        <measure>
          <title>PCA Fentanyl Consumption</title>
          <description>PCA fentanyl consumption and adverse effects are recorded during the first 24 h after surgery.</description>
          <units>μg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="395.0" spread="138.5"/>
                    <measurement group_id="O2" value="359.8" spread="120.2"/>
                    <measurement group_id="O3" value="247.1" spread="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>*1/*1</title>
          <description>Grouped by CYP3A4*1G polymorphism, wild-type homozygote</description>
        </group>
        <group group_id="E2">
          <title>*1/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1/*1G: mutant heterozygote</description>
        </group>
        <group group_id="E3">
          <title>*1G/*1G</title>
          <description>Grouped by CYP3A4*1G polymorphism,*1G/*1G: mutant homozygote</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="103"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The preoperative and postoperative data were not all integrallty recorded in a relative short period and entered into Excel.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Zhang Xianwei</name_or_title>
      <organization>Huazhong University of Science&amp;Technology</organization>
      <phone>027 83662853</phone>
      <email>ourpain@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

